Fusion constructs containing active sections on TNF ligands

Details Fusion constructs containing active sections on TNF ligands Fusion constructs containing active sections on TNF ligands

2002-08-21

2010-06-15

Kolker, Daniel E. (Department: 1649)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C435S252300, C435S320100, C435S325000, C530S387300, C536S023400

Reexamination Certificate

active

07736657

ABSTRACT:
Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.

REFERENCES:
patent: 6046310 (2000-04-01), Queen et al.
patent: 6316256 (2001-11-01), Tykocinski et al.
patent: 6617135 (2003-09-01), Gillies et al.
patent: 7115555 (2006-10-01), Zonana et al.
patent: WO 9404678 (1994-03-01), None
patent: WO 00/63253 (2000-10-01), None
patent: WO 01/24811 (2001-04-01), None
Mohler et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. Aug. 1, 1993;151(3):1548-61.
Kondo et al. The medaka rs-3 locus required for scale development encodes ectodysplasin-A receptor. Curr Biol. Aug. 7, 2001;11(15):1202-6.
Peppel et al. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med. Dec. 1, 1991;174(6):1483-9.
Definition of “hexamer,” http://www.biology-online.org/dictionary/Hexamer, retrieved on Jun. 8, 2009.
Schneider et al. Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A. J Biol Chem. Jun. 1, 2001;276(22):18819-27. Epub Mar. 14, 2001.
N. Holler et al, “Two Adjacent Trimeric Fas Lidgands are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex”, Molecular and Cellular Biology, Feb. 2003, vol. 23, No. 4, p. 1428-1440.
S. Bulfone-Paus et al., “An Interleukin-2-IgG-Fas Ligand Fusion Protein Suppresses Delayed-Type Hypersensitivity in Mine by Triggering Apoptosis in Activated T Cells as a Novel Strategy for Immunosuppression”, Transplantation, vol. 69, No. 7, Apr. 15, 2000, p. 1386-1391.
W. C. Fanslow et al., Structural Characteristics of CD40 Ligand that Determine Biological Function, Immunology, vol. 6, 1994, p. 267-278.
P. R. Baum et al., Molecular Characterization of Murine and Human OX40/OX40 Ligand Systems: Identification of a Human OX40 Ligand as the TLV-1-Regulated Protein gp34, The EMBO Journal, vol. 13, No. 17, 1994, p. 3992-4001.
P. Schneider et al., “Apoptosis Induced by Death Receptors”, Pharmaceutica Acta Helvetiae, 74 (2000) p. 281-286.
N. Holler et al., “Development of Improved Soluble Inhibitors of FasL and CD40L Based on Oligomerized Receptors”, Journal of Immunological Methods, 237 (2000), p. 159-173.
J. Bodmer et al., “The Molecular Artchitecture of the TNF Superfamily”, Trends in Biochemical Sciences, vol. 27, Jan. 1, 2002, p. 19-26.

Affiliated with

Also associated with

Rating

Fusion constructs containing active sections on TNF ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion constructs containing active sections on TNF ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion constructs containing active sections on TNF ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4243284